GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (BUE:ABBV) » Definitions » Debt-to-Revenue

AbbVie (BUE:ABBV) Debt-to-Revenue : 1.23 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbbVie Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

AbbVie's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ARS11,947,784 Mil. AbbVie's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ARS55,612,802 Mil. AbbVie's annualized Revenue for the quarter that ended in Sep. 2024 was ARS54,976,918 Mil. AbbVie's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 1.23.


AbbVie Debt-to-Revenue Historical Data

The historical data trend for AbbVie's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Debt-to-Revenue Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 1.88 1.37 1.09 1.09

AbbVie Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 1.04 1.50 1.22 1.23

Competitive Comparison of AbbVie's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, AbbVie's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where AbbVie's Debt-to-Revenue falls into.



AbbVie Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

AbbVie's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2595951.002 + 18842034.017) / 19608798.018
=1.09

AbbVie's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(11947784.475 + 55612802.056) / 54976917.584
=1.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


AbbVie Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of AbbVie's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie Business Description

Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).